Unichem Laboratories Limited (UNICHEMLAB) AI Stock Analysis

Unichem Laboratories Limited

(NSE:UNICHEMLAB)

Select Model

Rating:68Neutral

Price Target:INR 514.00▲(2.01% Upside)

Action:downgraded

Date:10/10/26

The overall score reflects improving fundamentals driven by stronger earnings and a solid, low-leverage balance sheet, offset by persistently weak and negative free cash flow, which is the main risk. Technicals indicate an intermediate uptrend but only neutral momentum and elevated volatility, keeping the near-term risk–reward balanced rather than strongly bullish. A reasonable earnings-based valuation provides support but not a significant margin of safety, resulting in a moderately attractive but not top-tier score.

Positive Factors

Conservative Balance SheetLow leverage and a growing equity base provide financial resilience and preserve flexibility to support operations or future investment. This conservative capital structure reduces balance-sheet strain and gives Unichem greater capacity to manage industry volatility over the next several quarters.

Negative Factors

Weak Cash ConversionPersistent negative operating and free cash flow means reported earnings are not translating reliably into cash resources. This can constrain internally funded growth, increase reliance on financial flexibility, and raise execution risk if investment needs remain high or operating conditions become less favorable.

Unichem Laboratories Limited (UNICHEMLAB) vs. iShares MSCI India ETF (INDA)

Market Cap: INR 35.71B
Dividend Yield: ―
Average Volume (3M): 11.35K
Price to Earnings (P/E): 11.6
Beta (1Y): 1.34
Revenue Growth: 9.43%
EPS Growth: 132.94%
Country: India
Employees: 2,815
Sector: General
Sector Strength: 55
Industry: Drug Manufacturers - Specialty & Generic

Unichem Laboratories Limited Business Overview & Revenue Model

Company Description

Unichem Laboratories Limited is an international pharmaceutical company engaged in the development, manufacturing, and commercialization of a wide array of medicinal products. The firm's portfolio features finished pharmaceutical formulations designe...

How the Company Makes Money

Unichem Laboratories makes money primarily by selling pharmaceutical products across a mix of business lines and geographies. Key revenue streams typically include: (1) Domestic formulations: revenue from marketing and distributing branded formulatio...

Unichem Laboratories Limited Financial Statement Overview

Summary

Revenue and net income have grown strongly with a clear turnaround from losses to double-digit net margins, and the balance sheet shows low leverage and rising equity, but persistently weak and volatile operating and free cash flow significantly dampen overall financial strength.

Income Statement

72Positive

Balance Sheet

82Very Positive

Cash Flow

38Negative

Financial statement breakdown
Breakdown	TTM	Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022
Income Statement
Total Revenue	23.08B	22.02B	21.11B	16.57B	13.25B	12.56B
Gross Profit	7.25B	6.60B	12.47B	3.17B	7.92B	8.07B
EBITDA	4.90B	4.49B	2.65B	742.36M	-456.07M	803.28M
Net Income	3.05B	2.53B	1.38B	-704.74M	-2.02B	330.62M
Balance Sheet
Total Assets	0	37.37B	35.69B	31.69B	31.93B	33.19B
Cash, Cash Equivalents and Short-Term Investments	2.89B	2.99B	895.80M	1.52B	1.89B	3.73B
Total Debt	0	5.00B	4.60B	2.48B	3.14B	3.49B
Total Liabilities	-27.17B	10.20B	11.19B	8.07B	7.58B	7.00B
Stockholders Equity	27.17B	27.17B	24.51B	23.62B	24.35B	26.18B
Cash Flow
Free Cash Flow	408.30M	-1.39B	-1.44B	-58.53M	-1.29B	-3.87B
Operating Cash Flow	994.40M	-156.90M	-70.20M	166.94M	-850.91M	-2.60B
Investing Cash Flow	-375.90M	1.86B	-2.41B	504.04M	2.03B	1.00B
Financing Cash Flow	259.10M	267.90M	1.84B	-1.06B	-813.00M	1.91B

Unichem Laboratories Limited Technical Analysis

Technical Analysis SentimentPositive

Last Price503.85

Price Trends

50DMA529.52Negative

100DMA521.11Negative

200DMA440.40Positive

Market Momentum

MACD-12.67Positive

RSI47.43Neutral

STOCH64.33Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:UNICHEMLAB, the sentiment is Positive. The current price of 503.85 is below the 20-day moving average (MA) of 509.54, below the 50-day MA of 529.52, and above the 200-day MA of 440.40, indicating a neutral trend. The MACD of -12.67 indicates Positive momentum. The RSI at 47.43 is Neutral, neither overbought nor oversold. The STOCH value of 64.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:UNICHEMLAB.

Unichem Laboratories Limited Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

IN:UNICHEMLAB against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IN:WINDLAS	68Neutral	INR 18.10B	28.77	―	0.69%	18.53%	1.89%
IN:UNICHEMLAB	68Neutral	INR 34.04B	11.64	―	―	9.43%	132.94%
IN:GUFICBIO	65Neutral	INR 41.34B	56.91	―	0.02%	16.70%	18.73%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
IN:MOREPENLAB	55Neutral	INR 62.30B	31.40	―	0.19%	30.20%	91.17%
IN:INDOCO	50Neutral	INR 19.23B	63.42	―	0.09%	10.75%	―
IN:HIKAL	47Neutral	INR 26.01B	-80.56	―	0.27%	-5.37%	-153.40%

* General Sector Average

Performance Comparison

IN:UNICHEMLAB and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
IN:UNICHEMLAB	Unichem Laboratories Limited	504.15	33.70	7.16%
IN:GUFICBIO	Gufic Biosciences Limited	415.90	89.23	27.32%
IN:HIKAL	Hikal Limited	220.65	-19.12	-7.98%
IN:INDOCO	Indoco Remedies Limited	215.85	-57.11	-20.92%
IN:MOREPENLAB	Morepen Laboratories Limited	108.05	59.92	124.50%
IN:WINDLAS	Windlas Biotech Ltd.	908.15	-20.18	-2.17%

Unichem Laboratories Limited Corporate Events

Exchange Seeks Clarification as Unichem Labs Shares See Volume Surge

Aug 25, 2026

A significant spike in trading volume has been recorded in the shares of Unichem Laboratories Limited, prompting closer attention from the stock exchange. The move signals heightened investor activity and possibly shifting sentiment toward the pharma...

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 10, 2026

Unichem Laboratories Limited AI Stock Analysis